Trial Profile
Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Acronyms DAAMSEL
- 15 Jun 2018 Results published in the Journal of Clinical Psychopharmacology
- 16 Mar 2017 Status changed from recruiting to completed.
- 20 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016.